外侧下丘脑区深部脑刺激通过食欲素通路促进创伤性脑损伤昏迷大鼠觉醒
本研究将55只Sprague-Dawley大鼠随机分为5组,评估外侧下丘脑区深部脑刺激(LHA-DBS)对创伤性脑损伤(TBI)昏迷大鼠的促醒作用。结果显示LHA-DBS组苏醒大鼠数量多于TBI组和拮抗剂组,且前额叶皮层α1-肾上腺素受体表达上调、GABAB受体表达下调,提示食欲素-OX1R通路参与促醒机制。
要点
- LHA-DBS可促进TBI昏迷大鼠苏醒,苏醒数多于TBI组和OX1R拮抗剂组。
- LHA-DBS上调前额叶皮层α1-AR表达并下调GABABR表达。
- 食欲素-OX1R通路可能介导LHA-DBS的促觉醒效应。
核心结论
- LHA-DBS促进TBI昏迷大鼠意识恢复,其机制可能涉及经食欲素-OX1R通路上调前额叶皮层α1-AR并下调GABABR表达。
研究设计与样本
- 研究纳入55只Sprague-Dawley大鼠,随机分为对照组、TBI组、刺激组(TBI+LHA-DBS)、拮抗剂组(TBI+SB334867+LHA-DBS)和拮抗剂对照组(TBI+生理盐水+LHA-DBS)。
- 采用自由落体法诱导昏迷,刺激组接受双侧LHA刺激(频率200 Hz,电压2-4 V,脉宽0.1 ms),每次刺激1小时,左右侧交替进行,间隔5分钟。
- 拮抗剂组先经脑室内注射食欲素受体1(OX1R)拮抗剂SB334867,再接受LHA-DBS。
- 采用I-VI意识量表与脑电图评估意识水平,Western blotting和免疫荧光检测OX1R、α1-AR及GABABR表达。
主要发现
- TBI组、刺激组、拮抗剂组和拮抗剂对照组分别有5、10、6和9只大鼠苏醒。
- 脑电图显示刺激组δ波比例低于TBI组和拮抗剂组(P < 0.05)。
- 刺激组LHA区OX1R表达高于TBI组(P < 0.05)。
- 刺激组前额叶皮层α1-AR表达高于TBI组和拮抗剂组(P < 0.05),GABABR水平低于TBI组和拮抗剂组(P < 0.05)。
- 拮抗剂组与拮抗剂对照组之间差异有统计学意义。
临床怎么用
- LHA可能是DBS促醒的潜在靶点,但当前证据仅来自大鼠TBI昏迷模型。
- 食欲素-OX1R通路及前额叶皮层α1-AR/GABABR表达变化或可作为促醒机制研究的候选标志。
局限性
- 研究仅为大鼠动物实验,样本量55只,结论不能直接外推至人类昏迷患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Previous studies have shown that deep brain stimulation (DBS) can improve the level of consciousness of comatose patients with traumatic brain injuries (TBIs). However, the most suitable targets for DBS are unknown, and the mechanisms underlying recovery remain to be determined. The aim of the present study was to assess the effects of lateral hypothalamic area-DBS (LHA-DBS) in comatose rats with TBIs. METHODS: A total of 55 Sprague-Dawley rats were randomly assigned to 5 groups: the control group, TBI group, stimulated (TBI+LHA-DBS) group, antagonist (TBI+SB334867+LHA-DBS) group, and antagonist control (TBI+saline+LHA-DBS) group. The rats in the control group had undergone a sham operation and anesthesia, without coma induction. Coma was induced using a free-fall drop method. The rats in the stimulated group received bilateral LHA stimulation (frequency, 200 Hz; voltage, 2-4 V; pulse width, 0.1 ms) for 1 hour, with 5-minute intervals between subsequent stimulations, which were applied alternately to the left and right sides of the lateral hypothalamus. The comatose rats in the antagonist group received an intracerebroventricular injection with an orexins receptor type 1 (OX1R) antagonist (SB334867) and then received LHA-DBS. A I-VI consciousness scale and electroencephalography were used to assess the level of consciousness in each group of rats after LHA-DBS. Western blotting and immunofluorescence were used to detect OX1R expression in the LHA and α1-adrenoceptor (α1-AR) subtype and gamma-aminobutyric acid β receptor (GABABR) expression in the prefrontal cortex. RESULTS: In the TBI, stimulated, antagonist, and antagonist control groups, 5, 10, 6, and 9 rats were awakened. The electroencephalographic readings indicated that the proportion of δ waves was lower in the stimulated group than in the TBI and antagonist groups (P < 0.05). Western blotting and immunofluorescence analysis showed that OX1R expression was greater in the stimulated group than in the TBI group (P < 0.05). The expression of α1-AR was also greater in the stimulated group than in the TBI and antagonist groups (P < 0.05). In contrast, the GABABR levels in the stimulated group were lower than those in the TBI and antagonist groups (P < 0.05). A statistically significant difference was found between the antagonist and antagonist control groups. CONCLUSIONS: Taken together, these results suggest that LHA-DBS promotes the recovery of consciousness in comatose rats with TBIs. Upregulation of α1-AR expression and downregulation of GABABR expression in the prefrontal cortex via the orexins and OX1R pathways might be involved in the wakefulness-promoting effects of LHA-DBS.
引用
- Dong X, Ye W, Tang Y, et al. Wakefulness-Promoting Effects of Lateral Hypothalamic Area-Deep Brain Stimulation in Traumatic Brain Injury-Induced Comatose Rats: Upregulation of α1-Adrenoceptor Subtypes and Downregulation of Gamma-Aminobutyric Acid β Receptor Expression Via the Orexins Pathway. World Neurosurg. 2021. PMID: 34062300. doi:10.1016/j.wneu.2021.05.089
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。